Argyropoulos, Georgios P. D. http://orcid.org/0000-0001-8267-6861
van Dun, Kim http://orcid.org/0000-0002-5212-8650
Adamaszek, Michael
Leggio, Maria http://orcid.org/0000-0003-3750-2760
Manto, Mario http://orcid.org/0000-0001-6034-4380
Masciullo, Marcella http://orcid.org/0000-0003-1368-7692
Molinari, Marco http://orcid.org/0000-0001-9808-9688
Stoodley, Catherine J. http://orcid.org/0000-0003-2629-0213
Van Overwalle, Frank http://orcid.org/0000-0002-2538-9847
Ivry, Richard B.
Schmahmann, Jeremy D. http://orcid.org/0000-0003-0706-5125
Funding for this research was provided by:
National Institutes of Health (NS105839, R15MH106957, R21DC014087)
Italian Ministry of Instruction, University and Research (RM11715C7E67E525)
Italian Ministry of Health (-)
Ricerca Finalizzata of the Italian Ministry of Health (RF-2011-02348213)
NIH-NINDS (-)
National Ataxia Foundation (-)
Ataxia Telangiectasia Children's Project (-)
MINDlink Foundation (-)
Strategic Research Program (SRP15)
Article History
First Online: 14 September 2019
Compliance with Ethical Standards
:
: Dr. Schmahmann discloses that he consults for Bayer, Biogen, Biohaven, and Cadent Pharmaceuticals; is on the scientific advisory boards of the National Ataxia Foundation, the Society for Research on the Cerebellum and Ataxias, and the executive of the American Neuropsychiatric Association; receives royalties from Oxford University Press, Elsevier, and MacKeith Press; and holds the license with the General Hospital Corporation to the Brief Ataxia Rating Scale, the Brief Ataxia Scale revised, the Cerebellar Cognitive Affective / Schmahmann Syndrome scale, the Cerebellar Neuropsychiatric Rating Scale, and the Patient Reported Outcome Measure for Ataxia (PROM-Ataxia). None of these disclosures represents a conflict of interest that may be perceived as biasing the content of this contribution. The other authors declare no competing financial interests.